Ginkgo Bioworks Q2 revenue falls 11%

Ginkgo Bioworks Holdings

07/08/2025 22:20

Overview

Ginkgo Q2 2025 rev falls to $50 mln, down from $56 mln yr/yr

Cell Engineering rev rises 8% to $39 mln, driven by biopharma growth

Biosecurity rev declines to $10 mln from $20 mln yr/yr

Co achieves $250 mln cost-reduction target ahead of schedule

Outlook

Ginkgo reaffirms 2025 total revenue of $167-$187 mln

Ginkgo expects 2025 Cell Engineering revenue of $117-$137 mln

Ginkgo expects 2025 Biosecurity revenue of at least $40 mln

Ginkgo aims for Adjusted EBITDA breakeven by end of 2026

Result Drivers

CELL ENGINEERING GROWTH - Cell Engineering revenue rose 8% to $39 mln, driven by demand from biopharma and government customers

BIOSECURITY DECLINE - Biosecurity revenue fell to $10 mln, impacted by reduced demand compared to prior year

COST REDUCTION - Achieved $250 mln annualized cost-reduction target ahead of schedule, aiding improved adjusted EBITDA

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Rev
$50 mln
Q2 EPS
-$1.1
Q2 Net Income
-$60.30 mln
Q2 Operating Expenses
$115.14 mln
Q2 Operating Income
-$65.54 mln
Q2 Pretax Profit
-$60.58 mln


Analyst Coverage

The current average analyst rating on the shares is "sell" and the breakdown of recommendations is 1 "strong buy" or "buy", no "hold" and 3 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Ginkgo Bioworks Holdings Inc is $8.00, about 74.5% below its August 6 closing price of $13.96

Press Release: ID:nPn5rPwLwa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)